Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures.
Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures. Patient's charts will be accessed on EPIC by the PI or delegated study personnel. The investigator's anticipate completion of this study by January 31, 2022.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Transplant free survival mortality | transplant will be measured by date of death, and discharge | Rate at 30 days |
| Difference in Demographics | co-morbidities, etiology of liver failure between those treated with MARS vs. controls | Rate at 30 days |
| Improvement in Transplant | Determine whether treatment with MARS can help facilitate improvement in HE, LOS, and ICU duration. | Rate at 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Demographics | age (years), gender (male/female), race (Caucasian, black, Hispanic, Asian, other), BMI (kg/m2) | January 1, 2019 to January 31, 2022 |
| Hepatorenal syndrome | Y/N |
Not provided
Inclusion Criteria:
• The patient was diagnosed with: Alcoholic hepatitis; AoCLF; OR Acute fulminant liver failure
• The patient underwent at least one round of dialysis using plasma exchange or MARSTM
Exclusion Criteria:
All patients who underwent MARS at MDMC will be included in the study population.
Not provided
Not provided
Not provided
Not provided
All patients meeting the inclusion criteria (Alcoholic hepatitis, AoCLF; or ALF who underwent at least one round of dialysis using plasma exchange or MARS from January 1, 2019 to December 15, 2020 will be included in the analysis.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Parvez Mantry, MD | Methodist | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Methodist Dallas Medical Center | Dallas | Texas | 75203 | United States |
Not provided
| ID | Term |
|---|---|
| D006519 | Hepatitis, Alcoholic |
| D017114 | Liver Failure, Acute |
| ID | Term |
|---|---|
| D006505 | Hepatitis |
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D008108 | Liver Diseases, Alcoholic |
Not provided
Not provided
Not provided
Not provided
Not provided
| (in hospital [date of death or discharge or transplant]) and at 30 days |
| Need for vasopressor support | Y/N | (in hospital [date of death or discharge or transplant]) and at 30 days |
| Sepsis (as measured by by QSOFA criteria): | Y/N | (in hospital [date of death or discharge or transplant]) and at 30 days |
| Need for CRRT as documented in the chart: | Y/N | (in hospital [date of death or discharge or transplant]) and at 30 days |
| ICU duration | days of date of ICU duration | date of ICU admission and date of discharge (or death) |
| long term dialysis | Need for long term dialysis (Y/N) | (in hospital [date of death or discharge or transplant]) and at 30 days |
| D020751 |
| Alcohol-Induced Disorders |
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D017093 | Liver Failure |
| D048550 | Hepatic Insufficiency |